Your browser is no longer supported. Please, upgrade your browser.
Order: Signal: Tickers:
Overview Valuation Financial Ownership Performance Technical Custom Charts Tickers Quotes Basic TA News Snapshot
Total: 68 #1
TickerACRX [NASD]
CompanyAcelRx Pharmaceuticals, Inc.
CountryUSA
IndustryMedical Appliances & Equipment
Market Cap401.72MEPS (ttm)-0.04
P/E-EPS this Y60.90%
Forward P/E-EPS next Y-9.50%
PEG-EPS past 5Y11.10%
P/S12.32EPS next 5Y-
P/B6.71EPS Q/Q107.70%
Dividend-Sales Q/Q860.00%
Insider Own35.67%Inst Own81.50%
Insider Trans0.00%Inst Trans1.59%
Short Float20.80%EarningsMar 02/a
Analyst Recom2.10Target Price11.22
Avg Volume353.39K52W Range5.22 - 13.64
Feb-26-15 06:07AMAcelRx upgraded by Mizuho Briefing.com
Feb-20-15 07:00AMAcelRx Pharmaceuticals to Participate at Two Upcoming Investor Events PR Newswire
Feb-13-15 04:31PMACELRX PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers EDGAR Online
Feb-09-15 06:07AMACELRX PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits EDGAR Online
Feb-04-15 07:00AMAcelRx Pharmaceuticals to Present at BIO CEO & Investor Conference PR Newswire
Jan-15-15 09:59AMWill the Second Time be a Charm for Biotech AcelRx After Their FDA Rejection? at TheStreet
Jan-13-15 04:50PMACELRX PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosur EDGAR Online
Dec-16-14 05:05PMAcelRx Pharmaceuticals Announces Departure of Richard A. King, President And CEO Benzinga
Dec-16-14 05:01PMACELRX PHARMACEUTICALS INC Files SEC form 8-K/A, Change in Directors or Principal Officers, Financial Statements and EDGAR Online
Dec-08-14 06:06AMACELRX PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers EDGAR Online
AcelRx Pharmaceuticals, Inc., a development stage specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute and breakthrough pain (BTP). Its principal product candidate is Zalviso, an investigational pre-programmed, non-invasive, handheld system that has completed Phase III clinical trials for the treatment of moderate-to-severe acute pain in adult patients in the hospital setting. The company is also developing ARX-04, a Sufentanil Single-Dose NanoTab, which has completed Phase II clinical trials for the treatment of moderate-to-severe acute pain to be administered by a healthcare professional to a patient in settings of acute pain, such as on the battlefield, in the emergency room, or in ambulatory care facilities. In addition, its product candidate pipeline consists of ARX-02, a Sufentanil NanoTab pain management system, which has completed Phase II clinical trials for the treatment of cancer patients who suffer from breakthrough pain (BTP); and ARX-03, a Sufentanil/Triazolam NanoTab, a Phase II clinical trials completed product designed to provide mild sedation, anxiety reduction, and pain relief for patients undergoing painful procedures in a physician's office. The company was formerly known as SuRx, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Redwood City, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
WAN MARK ADirectorMar 10Sale12.36835,32710,324,642126,153Mar 11 02:34 PM
WAN MARK ADirectorMar 07Sale12.30164,6732,025,400137,403Mar 11 02:34 PM
TickerACUR [NASD]
CompanyAcura Pharmaceuticals, Inc.
CountryUSA
IndustryDrug Delivery
Market Cap42.96MEPS (ttm)-0.28
P/E-EPS this Y-45.00%
Forward P/E-EPS next Y64.50%
PEG-EPS past 5Y-24.60%
P/S143.21EPS next 5Y-
P/B5.50EPS Q/Q14.30%
Dividend-Sales Q/Q0.00%
Insider Own0.40%Inst Own48.30%
Insider Trans-46.69%Inst Trans0.28%
Short Float1.27%EarningsMar 02/a
Analyst Recom2.00Target Price1.00
Avg Volume149.78K52W Range0.41 - 2.10
Mar-02-15 04:15PMAcura Pharmaceuticals Announces Fourth Quarter and Full Year 2014 Financial Results Marketwired
Feb-27-15 06:33AMAcura Pharma upgraded by MLV & Co Briefing.com
Feb-23-15 06:30AMAcura Pharmaceuticals to Host 2014 Financial Results Conference Call on March 3, 2015 Marketwired
Feb-16-15 06:30AMAcura Pharmaceuticals Initiates Clinical Study of Meth-Resistant Nexafed(R) Extended-Release Formulations Marketwired
Feb-05-15 06:15AMAcura Pharmaceuticals Expands Meth-Resistant Decongestant Line With NEXAFED(R) Sinus Pressure + Pain Marketwired
Jan-08-15 06:00AMAcura Pharmaceuticals Partners With Egalet Corporation to Commercialize Immediate Release Oxycodone Product Utilizing Acura's Aversion(R) (Abuse-Deterrent) Technology Marketwired
Dec-23-14 04:01PMACURA PHARMACEUTICALS, INC Files SEC form 8-K, Other Events EDGAR Online
Dec-23-14 06:00AMAcura Pharmaceuticals Acknowledges Distribution of Nexafed(R) by Kmart Pharmacy Marketwired
Dec-12-14 11:09AMACURA PHARMACEUTICALS, INC Files SEC form 8-K/A, Change in Directors or Principal Officers EDGAR Online
Dec-11-14 04:03PMACURA PHARMACEUTICALS, INC Files SEC form 8-K, Change in Directors or Principal Officers EDGAR Online
Acura Pharmaceuticals, Inc., a specialty pharmaceutical company, researches, develops, and commercializes products to address medication abuse and misuse utilizing its proprietary Aversion and Impede technologies. The company's products include Oxecta tablets, a Schedule II narcotic indicated for the management of acute and chronic moderate to severe pain; and Nexafed, a pseudoephedrine HCl tablet that is used as a nasal decongestant in various non-prescription and prescription cold, sinus, and allergy products. It has seven additional opioid products, including hydrocodone bitartrate/acetaminophen, methadone HCl, morphine sulfate, oxycodone HCl/acetaminophen, oxymorphone HCl, and tramadol HCl tablets utilizing Aversion technology in various stages of development. The company has a license, development, and commercialization agreement with King Pharmaceuticals Research and Development, Inc. to manufacture and commercialize Oxecta products in the United States, Canada, and Mexico. Acura Pharmaceuticals, Inc. was founded in 1935 and is based in Palatine, Illinois.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
CLAUDIUS LLC10% OwnerJan 12Sale0.6435,00022,45610,957,621Jan 12 06:21 PM
CLAUDIUS LLC10% OwnerJan 09Sale0.6536,00023,43610,992,621Jan 12 06:21 PM
CLAUDIUS LLC10% OwnerJan 08Sale0.60100,00060,18011,028,621Jan 12 06:21 PM
SKELLY WILLIAM GDirectorMay 22Sale1.234,6005,6585,000May 22 04:01 PM
SKELLY WILLIAM GDirectorMay 20Sale1.215,0006,0529,600May 21 04:06 PM
TickerAERI [NASD]
CompanyAerie Pharmaceuticals, Inc.
CountryUSA
IndustryDrug Manufacturers - Major
Market Cap693.74MEPS (ttm)-1.93
P/E-EPS this Y61.10%
Forward P/E-EPS next Y-24.50%
PEG-EPS past 5Y0.00%
P/S-EPS next 5Y-
P/B16.72EPS Q/Q95.00%
Dividend-Sales Q/Q-
Insider Own47.57%Inst Own95.60%
Insider Trans-17.41%Inst Trans0.10%
Short Float6.38%EarningsMar 02/a
Analyst Recom1.60Target Price40.40
Avg Volume280.19K52W Range13.66 - 32.50
Mar-02-15 05:16PMAerie reports 4Q loss AP
Mar-02-15 04:34PMAERIE PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and EDGAR Online
Mar-02-15 04:01PMAerie Pharmaceuticals Reports Fourth Quarter and Full Year 2014 Financial Results and Provides Business and Product Development Update Business Wire
Feb-27-15 04:53PMAERIE PHARMACEUTICALS INC Files SEC form 10-K, Annual Report EDGAR Online
Feb-24-15 04:02PMAERIE PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exh EDGAR Online
Feb-23-15 04:07PMAERIE PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits EDGAR Online
Feb-18-15 01:14PM4 Stocks Breaking Out on Big Volume: Zillow, Aerie and More at TheStreet
Feb-18-15 06:17AMAERIE PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits EDGAR Online
Feb-18-15 06:00AMAerie Pharmaceuticals Announces Potential Breakthroughs with New Preclinical Research Business Wire
Feb-17-15 04:05PMAerie Pharmaceuticals Announces Rhopressa Presentation at 2015 Meeting of the Association for Ocular Pharmacology and Therapeutics Business Wire
Aerie Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, is focused on the discovery, development, and commercialization of first-in-class glaucoma therapies. Its lead product candidate, Rhopressa, is a once-daily triple-action eye drop, which demonstrated the ability to reduce intraocular pressure (IOP) in patients with open-angle glaucoma and ocular hypertension in a Phase 2b clinical trial. The company is conducting two Phase 3 registration trials in the U.S. to demonstrate non-inferiority of IOP lowering for Rhopressa compared to timolol, as well as commencing a third safety-only Phase 3 registration trial of Rhopressa in Canada. It also develops once-daily quadruple-action Roclatan, a single drop combination of Rhopressa with latanoprost, which has completed a 28-day Phase 2b clinical trial. In addition, the company is taking preparatory steps for Phase 3 registration trials for Roclatan. Aerie Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Bedminster, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Clarus Lifesciences II, L.P.10% OwnerJan 08Sale31.11175,0005,444,2503,324,259Jan 12 09:44 AM
Clarus Lifesciences II, L.P.10% OwnerDec 29Sale30.036,214186,6063,522,879Dec 30 10:09 AM
Clarus Lifesciences II, L.P.10% OwnerDec 26Sale30.0574,5102,239,0263,529,093Dec 30 10:09 AM
Clarus Lifesciences II, L.P.10% OwnerDec 23Sale30.002637,8903,603,603Dec 24 03:10 PM
Clarus Lifesciences II, L.P.10% OwnerDec 22Sale30.3649,4411,501,0293,603,866Dec 24 03:10 PM
TickerALEX [NYSE]
CompanyAlexander & Baldwin, Inc.
CountryUSA
IndustryReal Estate Development
Market Cap1.99BEPS (ttm)0.56
P/E72.70EPS this Y77.80%
Forward P/E36.68EPS next Y-5.53%
PEG5.32EPS past 5Y0.60%
P/S3.43EPS next 5Y13.67%
P/B1.63EPS Q/Q450.00%
Dividend0.49%Sales Q/Q136.70%
Insider Own2.10%Inst Own77.50%
Insider Trans2.93%Inst Trans-3.06%
Short Float2.78%EarningsMar 02/a
Analyst Recom1.70Target Price53.20
Avg Volume195.16K52W Range33.98 - 45.07
Mar-02-15 09:15PMAlexander & Baldwin's The Collection condo project in Honolulu 93% sold at bizjournals.com
Mar-02-15 07:45PMAlexander & Baldwin needs more time to finalize 2014 income statements at bizjournals.com
Mar-02-15 07:08PM10-K for Alexander & Baldwin, Inc. Company Spotlight
Mar-02-15 05:00PMAlexander & Baldwin Inc Earnings Call scheduled for 5:00 pm ET today CCBN
Mar-02-15 04:48PMALEXANDER & BALDWIN, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and EDGAR Online
Mar-02-15 04:21PM4:21 pm Alexander & Baldwin reports Q4; co will file for extension of 2014 10-k filing date Briefing.com
Mar-02-15 04:02PMAlexander & Baldwin Reports Solid Fourth Quarter And Full-Year 2014 Operating Results; Will File For Extension Of 2014 10-K Filing Date PR Newswire
Mar-02-15 07:07AMQ4 2014 Alexander & Baldwin Inc Earnings Release - 4:00 pm ET CCBN
Feb-27-15 12:00PMJLL Raises Credit Facility to $2B, Extends Date Till 2020 - Analyst Blog Zacks
Feb-27-15 09:39AMSt. Joe Incurs Loss in Q4, Revenues Fall Year over Year - Analyst Blog Zacks
Alexander & Baldwin, Inc., together with its subsidiaries, primarily provides real estate development and leasing services. The company operates through four segments: Real Estate Development and Sales, Real Estate Leasing, Natural Materials and Construction, and Agribusiness. The Real Estate Development and Sales segment is involved in the stewardship, planning, entitlement, development, and sale of land, and commercial and residential properties principally in Hawaii. The Real Estate Leasing segment owns, operates, and manages retail, office, and industrial properties in Hawaii and on the Mainland, as well as leases land in Hawaii. The Natural Materials and Construction segment mines, processes, and sells basalt aggregate; imports sand and aggregates for sale and use; imports and markets liquid asphalt; manufactures and markets asphaltic concrete; manufactures and supplies precast/prestressed concrete products; provides and markets various construction- and traffic-control-related products and services; and performs asphalt paving as prime contractor and subcontractor. The Agribusiness segment produces bulk raw sugar, specialty food grade sugars, and molasses; markets and distributes specialty food-grade sugars; provides general trucking services, and mobile equipment maintenance and repair services; leases agricultural land to third parties; and generates and sells electricity, as well as provides raw sugar marketing and transportation services. The company was formerly known as A & B II, Inc. and changed its name to Alexander & Baldwin, Inc. in June 2012. Alexander & Baldwin, Inc. was founded in 1870 and is headquartered in Honolulu, Hawaii.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BENJAMIN CHRISTOPHER JPresident & COOJan 26Option Exercise0.003,060079,997Jan 27 05:07 PM
CHING MEREDITH JSr. Vice Pres. Gov't Rel.Jan 26Option Exercise0.001,275045,110Jan 27 05:07 PM
CHUN NELSON N SSr. Vice Pres. & CLOJan 26Option Exercise0.001,420060,596Jan 27 05:07 PM
Ito Paul KSr. Vice Pres. and CFOJan 26Option Exercise0.002,186018,449Jan 27 05:08 PM
KURIYAMA STANLEY MChairman & CEOJan 26Option Exercise0.005,0640217,652Jan 27 05:08 PM
TickerANV [AMEX]
CompanyAllied Nevada Gold Corp.
CountryUSA
IndustryGold
Market Cap117.27MEPS (ttm)-0.71
P/E-EPS this Y-98.10%
Forward P/E-EPS next Y-16.70%
PEG-EPS past 5Y14.90%
P/S0.36EPS next 5Y-
P/B0.13EPS Q/Q-
Dividend-Sales Q/Q0.30%
Insider Own8.35%Inst Own43.20%
Insider Trans0.00%Inst Trans-17.04%
Short Float30.50%EarningsMar 02/a
Analyst Recom3.60Target Price1.22
Avg Volume3.81M52W Range0.72 - 6.70
Feb-26-15 04:39PMAllied Nevada Golds Bondholders Said to Consider Injecting Cash at Bloomberg
Feb-20-15 11:50AMWill Allied Nevada Gold (ANV) Turn It Around This Earnings? - Analyst Blog Zacks
Jan-23-15 03:01PMAllied Nevada Gold (ANV) Stock Falls Today as Gold Prices Decline at TheStreet
Jan-21-15 12:05PMAllied Nevada Gold (ANV) Stock Falls Today After Preliminary Full-Year Production Announcement at TheStreet
Jan-21-15 08:45AMAllied Nevada Announces Preliminary Full Year 2014 Gold and Silver Sales Increase 19% and 115%, Respectively, Year-Over-Year Marketwired
Jan-20-15 11:55AMAllied Nevada Gold (ANV) Stock Advances Today as Gold Prices Rise at TheStreet
Jan-16-15 10:58AMAllied Nevada Gold (ANV) Stock Is Up Today as Gold Prices Climb at TheStreet
Jan-12-15 02:14PMAllied Nevada Gold (ANV) Stock Surging Today as Gold Prices Gain at TheStreet
Jan-12-15 09:31AMCan Billionaire John Paulson Bounce Back With Health Care? at TheStreet
Dec-17-14 12:25PMParamount Gold And Silver Soars 35% On Coeur Mining Acquisition Benzinga
Allied Nevada Gold Corp., a gold producer, is engaged in the mining, development, and exploration of properties in Nevada. The company's principal products comprise unrefined gold and silver bars. It operates the Hycroft Mine, an open pit heap leach operation located to the west of Winnemucca, Nevada. The company's properties also include Maverick Springs, Mountain View, Wildcat, and Pony Creek/Elliot Dome. In addition, it has approximately 73 other exploration properties. Allied Nevada Gold Corp. was incorporated in 2006 and is headquartered in Reno, Nevada.
TickerAPL [NYSE]
CompanyAtlas Pipeline Partners, L.P.
CountryUSA
IndustryOil & Gas Pipelines
Market Cap2.66BEPS (ttm)-0.81
P/E-EPS this Y-337.20%
Forward P/E40.84EPS next Y413.39%
PEG-EPS past 5Y28.40%
P/S0.97EPS next 5Y35.10%
P/B1.29EPS Q/Q119.70%
Dividend9.61%Sales Q/Q36.40%
Insider Own1.10%Inst Own52.70%
Insider Trans0.00%Inst Trans6.28%
Short Float4.51%EarningsMar 02/a
Analyst Recom3.10Target Price37.00
Avg Volume1.32M52W Range21.52 - 36.32
Feb-25-15 11:06AMIridian enters into a new position in Targa Resources Market Realist
Mar-02-15 09:25AMHouston midstream companies close major acquisitions at bizjournals.com
Feb-27-15 05:15PMAtlas Energy And Atlas Pipeline Complete Mergers With Targa Resources Corp. And Targa Resources Partners PR Newswire
Feb-24-15 06:03AMATLAS PIPELINE PARTNERS LP Files SEC form 8-K, Submission of Matters to a Vote of Security Holders, Other Events EDGAR Online
Feb-20-15 11:35AMAtlas Energy And Atlas Pipeline Unitholders Approve Mergers With Targa Resources Corp. And Targa Resources Partners PR Newswire
Feb-19-15 08:35AMBoardwalk Pipeline Partners To Join The Alerian Natural Gas MLP Index PR Newswire
Feb-19-15 08:35AMBoardwalk Pipeline Partners To Join The Alerian MLP Index And Alerian MLP Equal Weight Index PR Newswire
Feb-19-15 08:35AMAlerian Announces A Special Rebalancing Of The Alerian MLP Infrastructure Index PR Newswire
Feb-12-15 06:03AMATLAS PIPELINE PARTNERS LP Files SEC form 8-K, Other Events EDGAR Online
Feb-10-15 10:46AMNobody Understands Debt -- Including Paul Krugman at Forbes
Atlas Pipeline Partners, L.P. operates in the gathering and processing segments of the midstream natural gas industry. It operates through two segments, Gathering and Processing; and Transportation, Treating, and Other. The company provides natural gas gathering, processing, and treating services primarily in the Anadarko, Arkoma, and Permian basins located in the southwestern and mid-continent regions of the United States and in the Eagle Ford Shale play in south Texas; natural gas gathering services in the Appalachian basin in the northeastern region of the United States; and natural gas liquid transportation services in the southwestern region of the United States. It has interests in and operates 14 natural gas processing plants with aggregate capacity of approximately 1,500 million cubic feet per day located in Oklahoma and Texas; a gas treating facility in Oklahoma; and approximately 11,200 miles of active natural gas gathering systems in Oklahoma, Kansas, Tennessee, and Texas. The company's transportation and treating operations consist of 17 gas treating facilities that provide contract treating services to natural gas producers in Arkansas, Louisiana, Oklahoma, and Texas. Atlas Pipeline Partners, L.P. was founded in 1999 and is based in Pittsburgh, Pennsylvania.
TickerARNA [NASD]
CompanyArena Pharmaceuticals, Inc.
CountryUSA
IndustryBiotechnology
Market Cap1.03BEPS (ttm)-0.24
P/E-EPS this Y80.00%
Forward P/E-EPS next Y-52.00%
PEG-EPS past 5Y51.20%
P/S30.11EPS next 5Y-
P/B12.23EPS Q/Q37.50%
Dividend-Sales Q/Q127.80%
Insider Own0.50%Inst Own48.30%
Insider Trans-7.30%Inst Trans7.03%
Short Float15.87%EarningsMar 02/a
Analyst Recom2.70Target Price7.58
Avg Volume8.18M52W Range3.26 - 7.24
Mar-02-15 06:45PMArena Pharmaceuticals Misses Q4 Expectations Benzinga
Mar-02-15 05:14PMArena Pharmaceuticals reports 4Q loss AP
Mar-02-15 04:01PMArena Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full Year 2014 Financial Results PR Newswire
Feb-27-15 04:22PMWill Arena Pharmaceuticals (ARNA) Disappoint on Q4 Earnings? - Analyst Blog Zacks
Feb-23-15 08:00AMArena Pharmaceuticals Announces Fourth Quarter and Full Year 2014 Financial Results Conference Call and Webcast on Monday, March 2 PR Newswire
Feb-20-15 03:47PMObesity Drugs: Orexigen Gains Market Share at Expense of Arena, Vivus at TheStreet
Feb-18-15 08:00AMArena Pharmaceuticals to Present at the 2015 RBC Capital Markets Healthcare Conference PR Newswire
Feb-03-15 05:00AMArena Pharmaceuticals Announces Marketing Approval in South Korea of BELVIQ® (lorcaserin HCl) for Weight Management PR Newswire
Feb-02-15 08:00AMArena Pharmaceuticals to Present at the 17th Annual BIO CEO & Investor Conference PR Newswire
Jan-23-15 04:52PMARENA PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online
Arena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel drugs that target G protein-coupled receptors. The company offers BELVIQ, a drug used to treat chronic weight management in adults. Its products under development include APD811, an agonist of the prostacyclin receptor, which has completed single- and multiple-ascending dose Phase I trials for the treatment of pulmonary arterial hypertension; and temanogrel, an inverse agonist of the serotonin 2A receptor for the treatment of thrombotic diseases, which has completed single- and multiple-ascending dose Phase I trials. The company's products under development also comprise APD334, an agonist of the sphingosine 1-phosphate subtype 1 receptor for the treatment of conditions related to autoimmune diseases, which has completed Phase I single-ascending dose trial; and APD371, an agonist of the cannabinoid receptor 2 that is in Phase I single-ascending dose trial for the treatment of pain. It also manufactures drug products under a manufacturing services agreement for Siegfried AG. The company was founded in 1997 and is based in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
SPECTOR STEVEN WEVP, General Counsel & SecJan 08Option Exercise6.1645,000277,200173,039Jan 08 09:08 PM
SPECTOR STEVEN WEVP, General Counsel & SecJan 08Sale6.2645,000281,700128,039Jan 08 09:08 PM
SHANAHAN WILLIAM R JRSVP & Chief Medical OfficerJan 07Option Exercise1.4950,00074,500100,000Jan 08 09:07 PM
SHANAHAN WILLIAM R JRSVP & Chief Medical OfficerJan 07Sale5.4950,000274,50050,000Jan 08 09:07 PM
LIEF JACKChairman, President and CEOSep 17Option Exercise1.49100,000149,000441,039Sep 19 04:50 PM
TickerBALT [NYSE]
CompanyBaltic Trading Limited
CountryUSA
IndustryShipping
Market Cap99.54MEPS (ttm)-0.25
P/E-EPS this Y53.80%
Forward P/E-EPS next Y0.00%
PEG-EPS past 5Y0.00%
P/S2.06EPS next 5Y32.00%
P/B0.26EPS Q/Q-25.00%
Dividend2.31%Sales Q/Q9.90%
Insider Own5.60%Inst Own88.80%
Insider Trans10.73%Inst Trans2.45%
Short Float15.99%EarningsMar 02/a
Analyst Recom2.00Target Price4.29
Avg Volume829.73K52W Range1.45 - 7.89
Mar-02-15 04:51PMBaltic Trading reports 4Q loss AP
Mar-02-15 04:32PMBaltic Trading Limited Announces Fourth Quarter Financial Results PR Newswire
Mar-02-15 09:30AMZacks Rank #5 Additions for Monday - Tale of the Tape Zacks
Feb-26-15 08:30AMBaltic Trading Limited Announces Fourth Quarter 2014 Conference Call and Webcast PR Newswire
Feb-17-15 09:30AMZacks Rank #5 Additions for Tuesday - Tale of the Tape Zacks
Feb-05-15 09:30AMZacks Rank #5 Additions for Thursday - Tale of the Tape Zacks
Feb-03-15 09:30AMZacks Rank #5 Additions for Tuesday - Tale of the Tape Zacks
Jan-30-15 01:54PMThis Global Economic Indicator Just Hit A 30-Year Low Yahoo Finance Contributors
Jan-21-15 09:30AMZacks Rank #5 Additions for Wednesday - Tale of the Tape Zacks
Jan-16-15 08:49AMShould You Get Rid of Baltic Trading (BALT) Now? - Tale of the Tape Zacks
Baltic Trading Limited is engaged in shipping business in the drybulk industry spot market worldwide. The company operates a fleet of drybulk ships that transport iron ore, coal, grain, steel products, and other dry bulk cargoes. As of October 29, 2014, it owned four Capesize, four Supramax, one Ultramax, and five Handysize vessels with an aggregate carrying capacity of approximately 1,159,000 deadweight tons. The company charters its vessels to trading houses, including commodities traders, as well as producers and government-owned entities. Baltic Trading Limited was founded in 2009 and is based in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Apollo Management Holdings GP,10% OwnerJan 20Buy1.79376,234673,0837,069,483Jan 26 05:08 PM
WOBENSMITH JOHN CPres, CFO, Secy and TreasurerNov 17Sale3.3464,000213,690564,968Nov 18 05:20 PM
TickerCHUY [NASD]
CompanyChuy's Holdings, Inc.
CountryUSA
IndustryRestaurants
Market Cap374.50MEPS (ttm)0.70
P/E32.54EPS this Y78.40%
Forward P/E29.66EPS next Y12.78%
PEG1.30EPS past 5Y0.00%
P/S1.60EPS next 5Y25.00%
P/B3.25EPS Q/Q11.80%
Dividend-Sales Q/Q19.80%
Insider Own6.32%Inst Own-
Insider Trans0.00%Inst Trans-5.44%
Short Float16.56%EarningsMar 02/a
Analyst Recom2.40Target Price27.14
Avg Volume284.15K52W Range18.40 - 43.40
Mar-02-15 04:43PMChuy's tops Street 4Q forecasts AP
Mar-02-15 04:15PMCHUY'S HOLDINGS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exh EDGAR Online
Mar-02-15 04:03PM4:03 pm Chuy's beats by $0.01, beats on revs Briefing.com
Mar-02-15 04:00PMChuys Holdings, Inc. Announces Fourth Quarter and Year-End 2014 Financial Results Business Wire
Mar-02-15 07:07AMQ4 2014 Chuy's Holdings Inc Earnings Release - After Market Close CCBN
Feb-27-15 04:52PMStocks Log Big Monthly Gains; Monster Hits Profit Zone at Investor's Business Daily
Feb-19-15 09:05AMCHUY'S HOLDINGS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits EDGAR Online
Feb-19-15 09:00AMChuy's Holdings, Inc. to Announce Fourth Quarter 2014 Results on March 2, 2015 GlobeNewswire
Jan-22-15 04:21PMTaking Stock: Winners and Losers, Stock of the Day at Bloomberg
Jan-22-15 09:43AMUPDATE: Wells Fargo Upgrades Chuy's Benzinga
Chuy's Holdings, Inc., through its subsidiary, Chuy's Opco, Inc., owns and operates restaurants under the Chuy's name in Texas and 13 states in the southeastern and midwestern United States. The company's restaurants provide Mexican and Tex Mex inspired food. As of November 4, 2014, it owned and operated 59 full-service restaurants in 14 states. The company was founded in 1982 and is headquartered in Austin, Texas.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Hatcher Michael C.VP of Real Estate DevelopmentMar 18Option Exercise2.7614,50040,02019,584Mar 19 04:09 PM
Hatcher Michael C.VP of Real Estate DevelopmentMar 18Sale39.0114,500565,6455,084Mar 19 04:09 PM
Biller Francis X.VP of Operations, SoutheastMar 04Option Exercise5.9915,00089,85040,836Mar 05 08:02 PM
Kittrell SusanControllerMar 04Option Exercise3.483501,218350Mar 05 08:01 PM
Lazenby PhillipVP of OperationsMar 04Option Exercise5.994,00023,9604,000Mar 05 08:01 PM
TickerCIM [NYSE]
CompanyChimera Investment Corporation
CountryUSA
IndustryREIT - Diversified
Market Cap3.31BEPS (ttm)0.64
P/E5.03EPS this Y9.40%
Forward P/E6.94EPS next Y14.85%
PEG0.66EPS past 5Y16.90%
P/S5.77EPS next 5Y7.65%
P/B0.92EPS Q/Q428.60%
Dividend11.18%Sales Q/Q46.00%
Insider Own0.20%Inst Own63.30%
Insider Trans0.00%Inst Trans-4.61%
Short Float1.31%EarningsMar 02/a
Analyst Recom3.10Target Price3.07
Avg Volume4.28M52W Range2.73 - 3.32
Mar-02-15 04:15PMChimera Investment Corporation Reports Net Income for 2014 of $589 Million or $0.57 Per Share, Core Earnings of $402 Million or $0.39 Per Share And GAAP Book Value of $3.51 Per Share. Business Wire
Feb-23-15 04:00PMReady To Invest In Financial Leverage Funds? at Investopedia
Feb-19-15 05:24PMChimera Investment Corporation Announces Dates of Fourth Quarter and Year-End 2014 Financial Results and Conference Call Business Wire
Jan-21-15 09:29PMWhat Dividend Stocks are the Billionaires Buying? at Forbes
Jan-21-15 05:52PMDividend Investing Like a Billionaire Yahoo Finance Contributors
Dec-19-14 02:09PMOmega Advisors lowers position in Chimera Investment Market Realist
Dec-18-14 04:46PMChimera Investment Corporation Declares 4th Quarter Dividend Business Wire
Nov-19-14 01:04PMCHIMERA INVESTMENT CORP Financials EDGAR Online Financials
Nov-13-14 08:00AMIt appears affordable care isnt adding to employment costs Market Realist
Nov-12-14 06:01AMCHIMERA INVESTMENT CORP Files SEC form 8-K/A, Results of Operations and Financial Condition, Financial Statements and EDGAR Online
Chimera Investment Corporation operates as a real estate investment trust (REIT) in the United States. The company, through its subsidiaries, invests in residential mortgage-backed securities (RMBS), residential mortgage loans, commercial mortgage loans, real estate-related securities, and various other asset classes. Its targeted asset classes include non-agency RMBS, such as investment-grade and non-investment grade classes; agency RMBS; insured loans; and first or second lien loans secured by multifamily properties, mixed residential or other commercial properties, retail properties, office properties, and industrial properties. The company's other asset-backed (ABS) securities include commercial mortgage-backed securities, debt and equity tranches of collateralized debt obligations, and consumer and non-consumer ABS, as well as hedging instruments. The company has elected to be taxed as a REIT for federal income tax purposes and would not be subject to income tax, if it distributes at least 90% of its REIT taxable income to its share holders. Chimera Investment Corporation was founded in 2007 and is based in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Dyer William B.Head of UnderwritingAug 15Buy3.2415,00048,600114,649Aug 18 04:01 PM
MARRIA MOHITChief Investment OfficerAug 14Buy3.2142,500136,425120,034Aug 18 04:01 PM
COLLIGAN ROBERT SChief Financial OfficerAug 14Buy3.2130,00096,30030,000Aug 14 04:38 PM
LAMBIASE MATTHEWCEO, President and DirectorAug 13Buy3.20100,000320,000582,000Aug 14 04:29 PM
1 2 3 4 5 6 7 next